Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Fujii

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Carcinogenesis|January 29, 2026
MSH2 Prevents Liver Tumorigenesis by Regulating Cell Cycle Checkpoints under Chronic InflammationShigeharu Nakano, Atsushi Takai, Eriko Iguchi, et al.
Cancer Science|May 31, 2017
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignanciesYosuke Minami, Hironobu Minami, Toshihiro Miyamoto, et al.
The Journal of Pathology|September 27, 2024
TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potentialMasako Mishima, Atsushi Takai, Haruhiko Takeda, et al.
Cancer Science|December 29, 2019
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, et al.
Eclinicalmedicine|December 5, 2022
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trialKeiko Imamura, Yuishin Izumi, Makiko Nagai, et al.
BMJ Open|December 5, 2019
Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patientsKeiko Imamura, Yuishin Izumi, Haruhiko Banno, et al.
Frontiers in Marine Science|September 20, 2019
Observational Needs for Improving Ocean and Coupled Reanalysis, S2S Prediction, and Decadal PredictionStephen G Penny, Santha Akella, Magdalena A Balmaseda, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Carcinogenesis|January 29, 2026
MSH2 Prevents Liver Tumorigenesis by Regulating Cell Cycle Checkpoints under Chronic InflammationShigeharu Nakano, Atsushi Takai, Eriko Iguchi, et al.
Cancer Science|May 31, 2017
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignanciesYosuke Minami, Hironobu Minami, Toshihiro Miyamoto, et al.
The Journal of Pathology|September 27, 2024
TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potentialMasako Mishima, Atsushi Takai, Haruhiko Takeda, et al.
Cancer Science|December 29, 2019
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, et al.
Eclinicalmedicine|December 5, 2022
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trialKeiko Imamura, Yuishin Izumi, Makiko Nagai, et al.
BMJ Open|December 5, 2019
Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patientsKeiko Imamura, Yuishin Izumi, Haruhiko Banno, et al.
Frontiers in Marine Science|September 20, 2019
Observational Needs for Improving Ocean and Coupled Reanalysis, S2S Prediction, and Decadal PredictionStephen G Penny, Santha Akella, Magdalena A Balmaseda, et al.
Pageof 8